STOCK TITAN
  1. Home
  2. Sec-filings
  3. CSTL
  4. [Form 4/A] CASTLE BIOSCIENCES INC Amended Insider Trading Activity

CSTL insider: 500 and 200 options exercised; matching sales filed

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4/A

Rhea-AI Filing Summary

Castle Biosciences (CSTL) reported insider transactions by its Chief Commercial Officer on an amended Form 4. On 11/11/2025, the officer exercised stock options at $3.38 and sold 500 shares at a weighted-average sale price of $35.39. On 11/12/2025, the officer exercised options at $3.38 and sold 200 shares at $35.40. These trades were made under a Rule 10b5-1 plan adopted on September 11, 2024.

Following the transactions, beneficial ownership was 84,527 shares direct and 2,230 shares indirect held by a family revocable trust. Derivative securities beneficially owned after the reported transactions were 15,903 stock options expiring on 03/12/2029. The amendment notes the option exercises were inadvertently omitted from the original filing and are now reported.

Positive

  • None.

Negative

  • None.
Insider Juvenal Tobin W
Role Chief Commercial Officer
Sold 700 shs ($25K)
Type Security Shares Price Value
Exercise Stock option (right to buy) 200 $0.00 --
Exercise Common Stock 200 $3.38 $676.00
Sale Common Stock 200 $35.40 $7K
Exercise Stock option (right to buy) 500 $0.00 --
Exercise Common Stock 500 $3.38 $2K
Sale Common Stock 500 $35.39 $18K
holding Common Stock -- -- --
Holdings After Transaction: Stock option (right to buy) — 15,903 shares (Direct); Common Stock — 84,727 shares (Direct); Common Stock — 2,230 shares (Indirect, By Tobin W and Susan M Juvenal Family Revocable Trust)
Footnotes (1)
  1. This transaction was made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 11, 2024. This transaction was executed in multiple trades at prices ranging from $35.38 to $35.40, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed at a price of $35.40. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Held by Tobin W and Susan M Juvenal Family Revocable Trust of which the Reporting Person and his spouse are the trustees and the Reporting Person, his spouse and their children are the beneficiaries. The exercise of the options was inadvertently omitted from the original Form 4 filing and is now being reported in this Amendment. The shares subject to the option are fully vested.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
Juvenal Tobin W
(Last) (First) (Middle)
C/O CASTLE BIOSCIENCES, INC.
505 S FRIENDSWOOD DRIVE, SUITE 401
(Street)
FRIENDSWOOD TX 77546
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
CASTLE BIOSCIENCES INC [ CSTL ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Commercial Officer
3. Date of Earliest Transaction (Month/Day/Year)
11/11/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
11/13/2025 		6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 11/11/2025 M(1) 500 A $3.38 85,027 D
Common Stock 11/11/2025 S(1) 500 D $35.39(2) 84,527 D
Common Stock 11/12/2025 M(1) 200 A $3.38 84,727 D
Common Stock 11/12/2025 S(1) 200 D $35.4(3) 84,527 D
Common Stock 2,230 I By Tobin W and Susan M Juvenal Family Revocable Trust(4)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock option (right to buy) $3.38 11/11/2025 M(1)(5) 500 (6) 03/12/2029 Common Stock 500 $0 16,103 D
Stock option (right to buy) $3.38 11/12/2025 M(1)(5) 200 (6) 03/12/2029 Common Stock 200 $0 15,903 D
Explanation of Responses:
1. This transaction was made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 11, 2024.
2. This transaction was executed in multiple trades at prices ranging from $35.38 to $35.40, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
3. This transaction was executed at a price of $35.40. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
4. Held by Tobin W and Susan M Juvenal Family Revocable Trust of which the Reporting Person and his spouse are the trustees and the Reporting Person, his spouse and their children are the beneficiaries.
5. The exercise of the options was inadvertently omitted from the original Form 4 filing and is now being reported in this Amendment.
6. The shares subject to the option are fully vested.
Remarks:
/s/ Frank Stokes, Attorney-in-fact 11/14/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did CSTL's insider report on the amended Form 4/A?

The Chief Commercial Officer exercised stock options at $3.38 and sold 500 shares at a weighted-average $35.39 on 11/11/2025, and sold 200 shares at $35.40 on 11/12/2025.

Were the CSTL insider trades under a trading plan?

Yes. The transactions were made pursuant to a Rule 10b5-1 plan adopted on September 11, 2024.

What are the insider’s holdings in CSTL after these transactions?

Beneficial ownership was 84,527 shares direct and 2,230 shares indirect held by a family revocable trust.

What option details were disclosed for CSTL?

Stock options with a $3.38 exercise price and 03/12/2029 expiration were involved; 15,903 derivative securities were beneficially owned after the transactions.

Why was this CSTL Form 4 filed as an amendment?

The filing states the option exercises were inadvertently omitted from the original and are now being reported.

What sale prices were reported for the CSTL shares?

Sales were reported at a weighted-average $35.39 on 11/11/2025 and $35.40 on 11/12/2025.